Screened 2026-09-11 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
ACM Research, Inc. holds its Markdown at $72.00. Consolidating, no directional conviction, held for 7 days.
As held on the ledger · 2026-09-11
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 7 days
Price at the screen
$72.00
Valuation
33.96 trailing · 24.89 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.95
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
10.37%
Below 33%
Interest-bearing debt is just 10.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
14.00%
Below 33%
Cash held in interest-bearing accounts and securities is 14.0% of assets, under the one-third limit.
Pass
Receivables
43.93%
Below 49%
Money owed to the company is 43.9% of assets, under the 49% limit.
Pass
Revenue purity
1.62%
Below 5%
Only 1.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. The price runs 1.4% above the base estimate.
Third-party analyst targets: 8 covering, consensus None. The average target sits +63% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Chip equipment makers face brutal cycle peaks
Every new semiconductor fab buildout sparks talk of endless demand, yet the equipment suppliers behind it live and die by the same boom and bust rhythm. ACM Research sells wet cleaning and packaging tools mostly into China, where revenue has climbed 34 percent lately, but the shares already price in far more growth than the numbers support at 37 times forward earnings.
We pass because the stock trades well above our fair value estimate and the business carries the classic cyclical trap signs. Peak cycle margins and earnings often look attractive on a headline multiple, yet they compress sharply when spending slows, and here the modest 9 percent profit margin and 8 percent return on equity give little cushion once orders turn.
China exposure adds another layer of volatility that could hit both sales and costs without warning. The ethical screen clears, but the valuation and industry pattern do not. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ACMR trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-20Markup$78.98-5.9%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 5.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 107% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 209%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (7 analysts) rates it strong buy, with a mean price target of $79.
2026-07-20Markup$83.92-10.7%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 10.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 107% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 209%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (7 analysts) rates it strong buy, with a mean price target of $79.
2026-07-18Markup$93.95+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 107% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 209%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (7 analysts) rates it strong buy, with a mean price target of $79.
2026-07-16Markup$93.95+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 107% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 209%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (7 analysts) rates it strong buy, with a mean price target of $79.
2026-07-03Markup$93.95+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$93.95Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.